Cite this answer
Atrial Natriuretic Peptide: quick citable summary
Atrial Natriuretic Peptide is listed by PeptaHub as a other peptide with a prescription legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “Atrial Natriuretic Peptide: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/atrial-natriuretic-peptide. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/atrial-natriuretic-peptide.
What is Atrial Natriuretic Peptide?
Nesiritide (Natrecor) is an FDA-approved recombinant human B-type natriuretic peptide used intravenously for acutely decompensated heart failure. It reduces preload and afterload through NPR-A-mediated vasodilation. Its role declined after ASCEND-HF showed no mortality or rehospitalization benefit.
Overview
Nesiritide (Natrecor) is an FDA-approved recombinant human B-type natriuretic peptide (BNP-32) structurally identical to the endogenous cardiac hormone. It is used intravenously for the treatment of acutely decompensated heart failure in patients with dyspnea at rest or with minimal activity. As a member of the natriuretic peptide family that includes ANP, it reduces preload, afterload, and promotes natriuresis.
Mechanism of action
Nesiritide binds to natriuretic peptide receptor A (NPR-A), a transmembrane guanylyl cyclase receptor expressed on vascular smooth muscle, endothelium, kidneys, and cardiac fibroblasts. Ligand binding activates the receptor's intrinsic guanylyl cyclase domain, generating the intracellular second messenger cyclic GMP (cGMP). Elevated cGMP activates protein kinase G (PKG), which phosphorylates myosin light chain phosphatase and reduces intracellular calcium, causing arterial and venous smooth muscle relaxation. This produces balanced vasodilation, reducing both preload (pulmonary capillary wedge pressure) and afterload (systemic vascular resistance) without reflex tachycardia. In the kidney, cGMP-mediated signaling in the collecting duct increases sodium excretion (natriuresis) and promotes diuresis. Nesiritide also suppresses the renin-angiotensin-aldosterone system and attenuates sympathetic nervous system activation, countering the neurohormonal overdrive characteristic of decompensated heart failure.
Reported study ranges
| Purpose | Route | Reported range | Frequency | Notes |
|---|---|---|---|---|
| acutely decompensated heart failure | intravenous | 2–2 mcg/kg | IV bolus, then 0.01 mcg/kg/min continuous infusion | 2 mcg/kg bolus over 1 minute, then 0.01 mcg/kg/min continuous infusion. Duration typically 24–48 hours. Monitor blood pressure closely; hypotension is the primary dose-limiting effect. Can reduce/omit bolus if systolic BP <100 mmHg. |
Reported ranges are for research context only. Consult a qualified healthcare professional before using any peptide.
Convert Atrial Natriuretic Peptide research-range units
Need to convert mg to mcg, dose volume, or U-100 syringe units? Use the peptide dose unit converter for educational calculation support.
Research summary
Nesiritide received FDA approval in 2001 for acutely decompensated heart failure. The VMAC trial (JAMA 2002) demonstrated reductions in pulmonary capillary wedge pressure versus placebo. Later safety concerns arose from a 2005 meta-analysis (Sackner-Bernstein) suggesting increased 30-day mortality and worsened renal function, which prompted the large ASCEND-HF trial (O'Connor et al., n=7,141). ASCEND-HF showed nesiritide gave only modest dyspnea relief and did not reduce death or rehospitalization, and did not confirm the mortality signal. Use has declined substantially; its role is now largely adjunctive. Note: despite these safety debates, the FDA label carries no boxed warning — hypotension is a standard warning, and the drug is contraindicated in cardiogenic shock and in patients with systolic BP below 100 mmHg.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Atrial Natriuretic Peptide for synergistic effects.
Legal status
FDA-approved since 2001 (Natrecor) for acutely decompensated heart failure with dyspnea at rest or minimal activity. Administered by intravenous bolus and continuous infusion in hospital settings with hemodynamic monitoring. Not a controlled substance. The label has NO boxed warning; hypotension is the dose-limiting warning. Contraindicated in cardiogenic shock and in patients with persistent systolic BP below 100 mmHg before therapy. Use has declined following ASCEND-HF.
Sourcing & access
Prescription required
Atrial Natriuretic Peptide is an FDA-approved prescription medication available through licensed healthcare providers, pharmacies, and label-appropriate access programs; compounded access depends on current FDA shortage status and compounding rules.
Frequently asked questions
Nesiritide, sold as Natrecor, is an FDA-approved recombinant human B-type natriuretic peptide consisting of 32 amino acids that is structurally identical to the endogenous cardiac hormone. It is administered intravenously in hospital settings for acutely decompensated heart failure in patients with dyspnea at rest or with minimal activity, reducing preload, afterload, and promoting natriuresis.
Nesiritide binds natriuretic peptide receptor A, a transmembrane guanylyl cyclase receptor, generating the second messenger cGMP in vascular smooth muscle, endothelium, and kidneys. The resulting protein kinase G activation drives balanced arterial and venous dilation that reduces preload and afterload without reflex tachycardia, while also promoting natriuresis and suppressing the renin-angiotensin-aldosterone system and sympathetic overdrive.
Use has declined substantially after the 7,141-patient ASCEND-HF trial showed nesiritide produced only modest dyspnea relief with no reduction in mortality or rehospitalization, following a 2005 meta-analysis that raised concerns about 30-day mortality and renal function. Nesiritide's role is now largely adjunctive. Its role narrowed on efficacy grounds; the FDA label does not carry a boxed warning.
Hypotension is the primary dose-limiting effect; the 2 mcg per kg bolus can be reduced or omitted if systolic blood pressure is below 100 mmHg. The drug is contraindicated in cardiogenic shock and in patients whose systolic BP is persistently below 100 mmHg before therapy. The label does not carry a boxed warning. Other reported side effects include headache, nausea, bradycardia, dizziness, back pain, and increased serum creatinine. Nesiritide is given only in hospital settings with continuous hemodynamic monitoring during the 24 to 48 hour infusion.
Research references
- Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial (VMAC)PubMed
- Effect of nesiritide in patients with acute decompensated heart failure (ASCEND-HF)PubMed
- Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applicationsReview
- Stretch-induced atrial natriuretic factor release utilizes a rapidly depleting pool of newly synthesized hormonePubMed